Zenas BioPharma宣布,其药物Obexelimab在针对免疫球蛋白G4相关疾病(IgG4-RD)的3期INDIGO注册试验中取得了积极成果。该试验达到了主要终点,显示出显著疗效和良好安全性,为后续监管申报奠定了坚实基础。
Zenas BioPharma宣布,其药物Obexelimab在针对免疫球蛋白G4相关疾病(IgG4-RD)的3期INDIGO注册试验中取得了积极成果。该试验达到了主要终点,显示出显著疗效和良好安全性,为后续监管申报奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.